Figure 7: Absence of DNAM-1 does not abrogate missing self killing.

In vivo killing of MHC-I-deficient spleen cells were assessed in CD226^−/− mice (a) or B6 wild-type mice after treatment with DNAM-1 mAb (c). CFSE-labelled B6 or MHC-I^−/− spleen cell suspensions were inoculated i.v. and rejection was assessed 44 h later in the spleen. (b) Frequency of NKG2A-SP NK cells gated on live, singlet CD3⁻NK1.1⁺Ly49r⁻ cells in CD226^−/− mice. Bar graphs show data from six (B6, B2m^−/−), seven (2 days) or four (2 weeks) mice per group of two independent experiments with at least two mice per group. (c,d) DNAM-1 was blocked by injection of 200 μg of anti-DNAM-1 (clone 3B3) for 2 days or 2 weeks every 5 days and rejection of CFSE-labelled B6 or MHC-I^−/− spleen cells was measured 44 h after inoculation of target cells (d) Frequency of NKG2A-SP NK cells gated on live, singlet CD3⁻NK1.1⁺Ly49r⁻ cells in B6 mice treated with anti-DNAM mAb for 2 days or 2 weeks. Bar graphs show data from 6 (B6), 4 (B2m^−/−) or 14 (CD226^−/−) mice per group of two independent experiments with at least two mice per group. P values are calculated with t-test and are depicted **P<0.01, ***P<0.001. Error bars denote s.d.